SLC12A2 and cerebral palsy: Since NKCC1 is abundantly expressed on other cell types in addition to astrocytes, such as endothelial cells which may also contribute to the cerebral oedema formation, the inhibition of this transporter is one of the options considered for the treatment of cerebral oedema (Deng et al., 2016).